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Review
Application of Yeast to Study the Tau and
Amyloid- Abnormalities of Alzheimer’s
Disease
Afsaneh Porzoor and Ian G. Macreadie∗
School of Applied Sciences, RMIT University, Bundoora, VIC, Australia
Abstract. The major molecules associated with Alzheimer’s disease, the phosphorylated protein tau and the 42 amino acid
peptide, amyloid- (A), have recently been analyzed in yeast. These yeast studies have provided major new insights into the
effects of tau and A and, at the same time, offered new approaches to rapidly search for chemicals that may be involved in
prevention of Alzheimer’s disease. The following review summarizes the role of yeast and its contribution in Alzheimer’s disease
research, and highlights important studies that have been conducted in this model organism.
Keywords: Alzheimer’s disease, amyloid-,Candida glabrata,Pichia pastoris,Saccharomyces cerevisiae,Schizosaccharomyces
pombe, tau
ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) currently is an irreversible
and progressive neurodegenerative disorder character-
ized by a decline in memory, intellect, comprehension,
and learning capacity. It is an epidemic disease that
most often occurs as an age-related disease. Among
people of 80 years of age, AD affects 25%. Currently
over 35.6 million individuals worldwide live with this
disease and it has been estimated that approximately
106 million people will suffer from AD by 2050 due to
increasing longevity [1]. These attributes make it one
of the biggest social burdens in the world.
AD results from death of neuronal cells and loss
of synapses and is typified by extracellular plaques
of amyloid- (A) and intracellular neurofibrillary
∗Correspondence to: Ian G. Macreadie, School of Applied Sci-
ences, RMIT University, Bundoora, VIC 3083, Australia. Tel.:
+61 3 9925 6627; Fax: +61 3 9925 7110, E-mail: ian.macreadie@
rmit.edu.au.
tangles of tau protein [2, 3]. The strong association of
A and tau levels, combined with their toxicity, impli-
cates them as causative agents in the development of
AD.
There have been many approaches to try to cure
or prevent AD. Some approaches are highly directed
such as immunotherapy using both passive and active
immunization [4, 5], while others involve dietary mod-
ification such as use of polyphenol and flavonoids
found in plant extracts [6–9]. Many of the previous
approaches for the treatment have been withdrawn due
to their side effects and lack of efficacy [10]. Stud-
ies on AD mainly involve cell culture and transgenic
mouse models, however, yeast studies are playing an
increasing role in understanding AD and in designing
chemo preventatives. This review summarizes some of
the recent research conducted in yeast to study AD with
a focus on tau and A. Possible drugs and screening
methods have also been listed. We have also attempted
to recapitulate the advantages, disadvantages, and pos-
sible limitations of this model system. The main focus
ISSN 1387-2877/12/$27.50 © 2013 – IOS Press and the authors. All rights reserved
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of this review is on Saccharomyces cerevisiae since
most studies exploit this species. Where alternative
species have been used, the names are given.
YEAST AS A MODEL ORGANISM
Yeast has a long history in biotechnology and
currently provides valuable new biopharmaceuticals,
including insulin and vaccines. Yeast has also provided
basic insights to the broad field of biological science,
including primary screening for the effect of chemicals,
and expression of recombinant proteins. Although out-
comes of any drug tests conducted in yeast should be
validated with more physiologically relevant models,
they still serve as a first line system to study many
diseases. Some of these developments and how they
have contributed to our knowledge of human health
and disease are briefly outlined in Table 1.
Yeast are among the simplest eukaryotes and share
many cellular mechanisms with all eukaryotic cells
including humans. This is particularly true about the
budding yeast S. cerevisiae. It has been the most
manipulated and exploited species and has long been
used as model organism for studying neurodegener-
ation (reviewed in [11–13]). It is also an established
model organism for analyzing conserved cell death
pathways such as apoptosis and necrosis [14]. Most
processes involved in neurodegenerative disorders
such as mitochondrial damage, oxidative stress, protein
aggregation and degradation can be analyzed within
yeast and often these can be coupled to high throughput
screens [15].
Yeast has been used as a model organism since early
1950 s, with the earliest studies providing an under-
standing of the mechanism of cell cycle and division
(reviewed in [16]). It was the first eukaryotic organ-
ism to have its entire genome sequenced in 1996 [17].
Knowledge of that sequence combined with the knowl-
edge of functions of many genes allowed a comparison
to sequences of other genomes, including the human
genome, where counterparts could be identified. It is
recognized that around 30% of currently known genes
involved in human disease have yeast orthologs [18].
YEAST FOR AD: UNDERSTANDING A
AND TAU
Yeast are widely used for the heterologous expres-
sion of proteins associated with human disease and for
expression of orthologues of proteins involved with
human disease. The genes encoding the two main pro-
teins/peptides implicated in AD, tau and A, do not
have orthologues in yeast but they can be expressed and
studied in yeast. A has received considerable atten-
tion because of a wealth of data that implicate A in the
development of AD. In particular, early onset or famil-
ial forms of AD (FAD) can occur as result of various
amino acid changes in A (shown in Fig. 1).
A is generated through cleavage of amyloid-
 protein precursor (APP) by -secretase (BACE)
and -secretase. The cleavage products are extremely
hydrophobic peptides that include A40, A42, and
A43, with the last two being more prone to aggrega-
tion and more neurotoxic while the former is found in
greater concentration in FAD compared to the latter
[19, 20]. In this review our focus is on A42, which we
abbreviate to A.
In order to study A, a few forms of these molecules
are employed including chemically-synthesized A,
intracellular fused A, and intracellular recombinant
forms. Studies with chemically-synthesized A on
Candida glabrata show an oligomerization-dependent
cytotoxicity [21]. This phenomenon is now driving new
approaches to block A toxicity through inhibition of
this process. The in vivo oligomerization was observed
when A was fused to yeast translational release fac-
tor, called MRF [22]. A caused oligomerization of
MRF leading to loss of MRF function and growth,
Table 1
Major advances in yeast studies that had a valuable impact on human health and disease
Yeast advance Impact on human biology
The yeast genome was the first eukaryotic genome to be
sequenced [67]
Human genes can be presumptively identified by similarity to yeast
counterparts
The yeast gene deletion collection is complete [68–71] Complementation studies with human genes can be performed
Yeast two hybrid is developed [72] Human protein interactions can be studied in yeast. Human gene libraries
are available for screening of human protein interactions
Yeast three hybrid is developed [73] RNA-protein interactions related to many human diseases (in particular
viral infections) can be studied. Receptors for small ligands can be
identified
Studies on yeast cell cycle [74–80] Schizosaccharomyces pombe studies recognized as applicable to cancer
research, leading to 2001 Nobel Prize
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Fig. 1. Amino acid changes leading to the early onset of Alzheimer’s disease. The amino acid sequence of A42 is given at the top. Amino
acid changes in familial Alzheimer’s disease have been highlighted in: Flemish mutation, causing angiopathy and patient frequently suffer from
intracerebral hemorrhage stroke [96]; Dutch mutation, causing cerebral hemorrhage with amyloidosis and premature death [97]; Iowa mutation,
causing cerebral amyloid angiopathy and occipital calcifications [98]; Arctic mutation, formation of plaques and tangle without any hemorrhage
or stroke [99].
whereas compounds that blocked peptide aggregation
led to growth. Similarly, Caine and colleagues [23]
made fusions of green fluorescent protein (GFP) to A
to examine oligomerization in the context of the fusion
protein. The purpose of this was to measure the amount
of correctly folded fusion protein in vivo through its
green fluorescence, while aggregation, oligomeriza-
tion, and degradation of the fusion protein would lead
to loss of fluorescence. It was found that relatively
small fractions of cells exhibited fluorescence but the
proportion of fluorescent cells was increased by treat-
ment with a folate [24], a vitamin associated with AD
chemo prevention. Also, intracellular expression of A
fused to GFP was shown to be associated with reduc-
tion of yeast cell growth and an increase in the heat
shock response (HSR) [23]. Increased HSR can pro-
vide protection of yeast cells from oxidative stress
[25]. Yeast assays employing A fused to MRF and
GFP appear very useful for monitoring effects of com-
pounds that influence the oligomerization or half-life
of A [26].
Yeast offers particular advantages for looking at
inhibitors of A oligomerization. Subunits of human
secretase complex such as APP can be expressed
and monitored individually in this model system.
Yeast studies are inexpensive and convenient in
comparison to in vitro studies of oligomerization
with extremely expensive and variable batches of
chemically-synthesized A that require denaturation
immediately prior to use. Frequently A is abandoned
and a surrogate peptide is used in its place. A sec-
ond advantage of in vivo studies of inhibitors of A
oligomerization is that compounds have to pass into the
cell. The ability to pass through membranes is a definite
requirement of any chemo preventative of AD, since
they are required to cross the blood-brain barrier and
inhibit formation of toxic oligomers within the brain.
Thirdly, cytotoxic compounds fail the primary screen-
ing because they inhibit yeast growth and production
of new A. Hence, toxic molecules can be eliminated
immediately. Fourthly, it is possible that compounds
that act indirectly may be identified. Such compounds
could include those that stimulate chaperones, or pro-
teins that bind to A. The contribution of yeast models
to our understanding of AD is shown in Table 2.
It is known that intracellular A can be stabilized
and is less toxic when fused to another protein, whereas
extracellular A is highly toxic to the yeast cells. While
A fusions have advantages as outlined earlier, it is
expected that fusions alter the properties of A, so a
very useful system is yeast producing native A. In a
recent study by D’Angelo and colleagues, intracellular
trafficking pathways were found to be essential and a
major determinant for the generation of toxic species of
A in S. cerevisiae regardless of whether Awas used
alone or fused to GFP [27]. In transgenic mouse models
for AD, A is produced by overproduction of human
APP and secretases [28, 29]. However, in S. cere-
visiae the A production is a complication that does
not occur due to lack of APP and the two secretases
(- and -secretase), whereas all three endoproteases
(-, -, and -secretase) has been detected in Pichia
pastoris [30].
Yeast can be made to produce native A using
a simple constitutive expression system (Macreadie,
unpublished). Yeast that produce A display a pro-
found growth stress and there is a strong pressure to
revert or suppress the effects. This is a useful attribute
that can be exploited to provide knowledge about how a
cell can overcome A toxicity. In addition, the growth
stress which is due to A toxicity can be used in screen-
ing for compounds that inhibit that stress. Work is
currently in progress in our laboratory to use these
strains to identify novel chemo preventatives and to
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Table 2
Role of yeast in revealing some of the factors believed to contribute to the development of Alzheimer’s disease
Factors that may lead to development of Yeast contribution
Alzheimer’s disease
A oligomerization Two hybrid system; A linked to LexA DNA binding domain and B42
transactivation domain [81]
Expression of A/Sup35p fusion protein [22, 82]
Expression of A/GFP fusion protein [23]
Cellular toxicity with external A External A is toxic to C. glabrata cells [25, 83]
Cellular toxicity with intracellular A Yeast models expressing intracellular A [84]
Reduction of -secretase cleavage of APP Expression of human APP in yeast [85]
Identification of two aspartyl proteases, Yap3 and Mkc7 [85]
Yeast GAL reporter system [86]
APP fused to invertase [87]
-secretase cleavage of APP Novel growth selection allowed human -secretase to be detected [88]
-secretase cleavage of APP Presenilin, nicastrin, APH-1. and PEN2 were identified as necessary components for
- secretase activity [89]
Tau hyperphosphorylation Human tau 3-R and 4-R isoforms expressed in yeast [48, 52, 90]
elucidate how “known chemo preventatives” impact
the toxicity.
Chemically-synthesized A has been shown to be
toxic to C. glabrata [21]. This has been an exciting
development that further supports equivalent results in
yeast and neuronal cells.
Neuronal cells are similarly affected. Neuronal cells
are terminally differentiated cells and A stimulates
cell division, which is a lethal event for them [31, 32].
It is yet to be determined how A kills C. glabrata.
In yeast, the toxicity assay is performed in water: A
is added to cells in water and after 16 hours of incu-
bation, cells are plated out to determine the viable
colony count. In the absence of A, cells in water
remain quiescent for many days with no loss of via-
bility. However, when a freshly prepared solution of
A is added, it binds the surface of the cells and kills
them within hours. If the A is allowed to form fib-
rils, it is no longer toxic. A recent simulation study has
shown that water can actually accelerate the fibril for-
mation in the A peptide similar to any hydrophobic
sequence whereas this process occurs more slowly in
hydrophilic sequences [33]. Likewise, changes within
A itself that prevent oligomerization also block the
toxic effect. Although A is generally regarded as a
toxic molecule, the opposite effect has occasionally
also been shown in both yeast and human cells. In
C. glabrata, A is protective from killing by sodium
hydroxide toxicity [25], and with adult neuronal stem
cells A can stimulate division [34].
In 1975, Weingarten and colleagues identified a pro-
tein factor named tau essential for microtubule assem-
bly [35]. However, when tau is hyper-phosphorylated
it caused formation of the neurofibrillary tangles which
are aggregates of tau formed in the intracellular region.
Although, controversies and questions still surrounds
toxicity of tau species [36], its presence has been iden-
tified as essential for A-induced neurotoxicity [37].
Like A, tangles are also associated with development
of AD [38] as their presence impairs nutrient transport
and perhaps cell signaling in the neuronal cells [39]. In
fact, an interrelated relationship between A and tau
has been reported whereby A accumulation triggers
upstream events such as inflammation and oxidative
stress leading to tau tangle formation and development
of neurodegenerative disease [40].
Tau clearance and processing is normally medi-
ated by both caspases and proteasome [41, 42] but in
the hyperphosphorylated form, tau become resistant
to the proteasome-mediated clearance [40, 43]. How-
ever, previous studies have shown that oxidative stress
by addition of millimolar concentrations of hydrogen
peroxide (H2O2) in primary oligodendrocyte culture
of rat brain can result in dephosphorylation of tau [44]
through activation of protein phosphatase 2A [45] and
an increase in the activity of protein phosphatase 1 [46].
The tau-expressing yeast model for studying AD
has been reviewed in depth previously [47]. S. cere-
visiae has no known ortholog for human tau; however,
human tau can be expressed in S. cerevisiae. Expres-
sion of various isoforms and mutant forms of tau in
yeast has resulted in similar features and physiog-
nomies to those of neuronal cells in AD [48, 49].
De Vos and colleagues have reported that tau aggre-
gation in those yeast expressing human tau does not
display a major tau-related growth phenotype [47].
However, tau-related growth phenotypes have not been
reported in stationary phase yeast cells as the majority
of previous studies have been conducted on exponen-
tially growing cells [50]. Also, in a tau-GFP fusion
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assay, Timmers and associates found that yeast lack
the microtubule binding site for tau whereas a common
binding site for animal and plant were identified [51].
Many important yeast orthologs of tau phosphatases
and kinases have been identified and are currently
under investigation [48, 49, 52]. Further, expression of
human tau in yeast has shown the presence of kinases
which result in generating many phosphorylated and
aggregated tau residues [52]. The phosphorylation of
tau by yeast is due to the presence of Mds1 and
Pho85 kinases which are orthologous of mammalian
kinases Gsk-3 and Cdk5, respectively. Additionally,
it appears that Pho85/Cdk5 has an inhibitory effect
on Mds1/Gsk-3 activity in both mammalian [53] and
yeast models [49]. Vanhelmont et al. also showed that
induction of reactive oxygen species in yeast, through
addition of Fe2+, caused an increase in formation of
oligomers and aggregates of tau in the absence of phos-
phorylation [49].
HIGH THROUGHPUT SCREENING FOR
AD CHEMO PREVENTATIVES
Impediments to research for a cure for AD have been
due to a number of causes. A large setback is probably
due to the huge reliance on animal models which have
provided fewer leads on chemo preventatives than epi-
demiological studies. Another difficulty is recognition
of the early markers in the disease pathway.
Therapeutic strategies and approaches that have
been developed to date include those with anti-
inflammatory, anti-amyloid formation or stability, and
antioxidant properties. Many compounds and chemi-
cals have provided promising results in cell culture and
animal models of AD. A list of some of these modu-
lating compounds that have shown potential benefit in
yeast models have been specified in Table 3.
Microbial models are useful in the screening of
AD drugs since they offer an ability to screen large
numbers of compounds in short time periods [26, 54,
55]. They can interrogate compounds that affect A
oligomer formation as well as killing and toxicity.
Wurth and colleagues have developed an Escherichia
coli that produces A fused to GFP and have used it to
identify candidates for AD chemo preventatives [56].
Although, it has some useful attributes like the yeast
model regarding its maintenance and cost, E. coli lacks
many of the human orthologous proteins that may be
identified in the yeast screening. Yeast are far simpler
than humans but this simplicity allows for better under-
standing the cellular mechanism and pathways to be
studied in depth. For instance, Treusch and associates
have taken advantage of this simplicity and have con-
ducted genome-wide overexpression in order to screen
for toxicity modulators in yeast models which resulted
in identification of several toxicity suppressors includ-
ing the yeast homolog of phosphatidylinositol binding
clathrin assembly protein (PICALM) and other endo-
cytic factors that have role in AD [57]. The authors also
show that after screening 5,000 genes with the aim of
finding A toxicity modifiers, they have identified 12
with human homologs, further implicating the benefit
of yeast models in the genome-wide association stud-
ies. In a similar way, Lo´pez and colleagues after screen-
ing two commercial chemical libraries have identified
four compounds capable of inhibiting A aggregation
in S. cerevisiae and Podospora anserine [58].
Thousands of human genes and proteins have coun-
terparts in yeast, and the “housekeeping” functions,
including defense mechanisms are highly similar.
Therefore compounds that interact with yeast cellular
processes are likely to act in the same way on human
cellular processes. Some of these cellular processes
include responses to reactive oxygen species, protein
misfolding, and apoptosis. In cases where there are
substantial differences between the two, re-engineered
yeast that can produce both APP and -secretase can
be used. Indeed yeast can also be used for screening of
inhibitors of -secretases [59, 60].
Aging has been known as one of most important fac-
tors for development of AD and that A can induce
Table 3
Selected number of chemicals/compounds tested in S. cerevisiae that may have benefits for treatment and prevention of AD and other age-related
diseases
Chemical/compound Findings References
Resveratrol Increased cell survival through stimulation of Sir-2 and increased DNA stability [91]
Quercetin Increased cell protection due to reduction in reactive oxygen species production,
glutathione oxidation, protein carbonylation, and lipid peroxidation
[92]
Clioquinol Affected metal (e.g., copper, iron, zinc) homeostasis [93]
Curcumin Chelated metal ions such as copper and iron, possibly preventing metal-mediated
toxicity of neuronal cells
[94]
Latrepirdine (Dimebon™) Increased autophagy and degradation of A [95]
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cell cycle events in the post-mitotic neuronal cells
which have been terminally differentiated. Accord-
ing to previous studies, age-dependent diseases can be
investigated in both S. cerevisiae and Schizosaccha-
romyces pombe by altering the growth conditions and
analyzing chronological lifespan or post-diauxic phase
[61]. This was achieved by growing cells into either
stationary or exponential phase, with the stationary
phase being more representative of the aged cells simi-
lar to the post-mitotic neuronal cells [62, 63]. Although
such studies have generated invaluable data on chrono-
logical aging and regulatory pathways [64, 65], it is
important to distinguish differences between senes-
cence and quiescence. Senescence occurs in terminally
differentiated neuronal cells, and age-related diseases
and refers to permanent proliferative cell cycle arrest
(reviewed in [66]), whereas quiescence is a reversible
event that occurs in those cells temporary arrested in
cycle due to trauma or stress induced by environment.
Another limitation of yeast models is the simplicity of
surrounding environment and the absence of inflamma-
tion, differentiation, and migration which is triggered
by A in neuronal cells.
For S. cerevisiae, collections of gene deletant strains
are readily available and deletions in other species can
also be made to study the gene-specific neurotoxic
effects. Additionally, S. cerevisiae strains producing
tau or A can be analyzed by gene arrays to deter-
mine effects on expression. Proteomic analyses may
also help to identify host proteins that modulate the
toxic effect and cell death.
Neuronal cells are also highly specific, complex,
differentiated cells with a unique morphology of den-
drites, axons, and synapses that changes with the
progression of AD, as well as through the effects of
their surrounding environment. Yeast cells on the other
hand are not differentiated in the same way, and they
can be quite adaptive and survive altered conditions.
However, it should be noted that less complexity in
this situation can be viewed as an advantage since
cDNA libraries of yeast genes are readily available
which can make molecular analyses easier. Further-
more, despite the fact S. cerevisiae does not carry any
homologous neurotoxic protein, conserved molecular
interactions mimic similar pathways of function and
transport.
CONCLUDING REMARKS
Powerful approaches in yeast technologies are now
being applied to the study of AD. Focusing on tau and
A, results can be obtained in hours, leading to new
insights about how these molecules contribute to dis-
ease progression in the brain. Further, the immense
power of genomic, proteomic, and metabolomic tools
can readily be employed in yeast studies to gain a
complete understanding of how tau and A exert their
effects. Coupled with this is the ability of high through-
put screening approaches in yeast that can readily
identify molecules that inhibit oligomerization or the
toxic effects of these compounds.
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